key: cord-0712362-ntw7dqcm
authors: Borgogna, Cinzia; De Andrea, Marco; Griffante, Gloria; Lai, Alessia; Bergna, Annalisa; Galli, Massimo; Zehender, Gianguglielmo; Castello, Luigi; Ravanini, Paolo; Cattrini, Carlo; Mennitto, Alessia; Gennari, Alessandra; Gariglio, Marisa
title: SARS‐CoV‐2 reinfection in a cancer patient with a defective neutralizing humoral response
date: 2021-07-20
journal: J Med Virol
DOI: 10.1002/jmv.27200
sha: a9967a5cf5b783af98251f56108aa80c17e5ec96
doc_id: 712362
cord_uid: ntw7dqcm

nan

To the Editor, Since August 2020, a series of cases of reinfection by a phylogenetically distinct variant of SARS-CoV-2 have been reported, raising pertinent questions on the heterogeneity of the natural immune response to SARS-CoV-2 infection that may not uniformly confer protective immunity to all individuals. [1] [2] [3] [4] [5] Specifically, reinfection seems more likely to occur in individuals whose immune system has been weakened by underlying comorbidities or therapies. [6] [7] [8] Here, we report a case of a 52-year-old male patient suffering from transitional cell carcinoma of the renal pelvis and ureter who was infected at two separate times with two genetically distant SARS-CoV-2 strains, with the reappearance of the first strain four months after the first infection. The patient's past medical history and treatments are summarized in Figure S1 . On June 23, 2020 (Day 0), he had a cough and fever and was diagnosed with COVID-19 by SARS-CoV- barely reached 50% of neutralization at the lowest serum dilution of 1:10 ( Figures 1D and S2 ). 9 The fact that VSV harbors the D614 form of the spike protein-the same found in the strain isolated on Day 0-and that the G614 form is reportedly unable to interfere with the neutralizing titer 10 rules out any detection bias of our approach, indicating that the patient did fail to mount an appropriate neutralizing humoral response.

Overall, this case highlights the concerning risk of reinfection in cancer patients who fail to mount an efficient neutralizing humoral response along with the underlying existence of persistent asymptomatic/undetectable infection.

Genomic evidence for reinfection with SARS-CoV-2: a case study

A case of SARS-CoV-2 reinfection in Ecuador

Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2. Clin Infect Dis

COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing

Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain

Persistence and evolution of SARS-CoV-2 in an immunocompromised host

Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer

The importance and challenges of identifying SARS-CoV-2 reinfections

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. npj Vaccines